DDD 2025 will be to late. El Palmar decision needs to be near term. COH until Q4 so more dilution. No real value for holder @ 5ml SOI and as we can see, no capital providers interest in STM ATM. Unfortunately the shortfall was not allocated.
My belief is sell a lease unless PD snags a Gina type injection.
These next lot of assays are sooo important. The team need excellent results, results that are truely phenomenal, exciting that will impact the EMR. NOT just inflated highlight of mediocre results. A lot of negative market sentiment started with the MD/Geo Pro-Active videos stating phenomena, exciting, massive when clearly the assays were very ordinary.
Fingers xed DDD these next 7 assays show a new viable target discovery that will compliment and add to Limon MR, NOT more assays on the Limon sheers zone. Management need to show their 8-9 months of surface targeting works program in the Western Zone are successful. Won't be a good look if another Western assay return not viable.
The SP took a battering at the August 23 failed target program and again with 8-9 months of no drilling. They've kicked of this current targeting program with a failure, first 2 Western assays were duds. Hope these next 7 assays are truely phenomenal.
GL mate
STM Price at posting:
1.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)